A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Description

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

Conditions

Advanced Solid Tumor

Study Overview

Study Details

Study overview

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Irvine

City of Hope At Orange County Lennar Foundation Cancer Center, Irvine, California, United States, 92618

Los Angeles

Valkyrie Clinical Trials, Los Angeles, California, United States, 90067

San Diego

Sharp Memorial Hospital, San Diego, California, United States, 92123

Plantation

Brcr Medical Center, Inc Dba Boca Raton Clinical Research, Plantation, Florida, United States, 33322

Tampa

H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States, 33612

Honolulu

University of Hawaii At Manoa, Honolulu, Hawaii, United States, 96813

Chicago

University of Chicago Medical Center, Chicago, Illinois, United States, 60637

Boston

Dana-Farber Cancer Institute - Parent., Boston, Massachusetts, United States, 02215

New York

Memorial Sloan-Kettering Cancer Center (Mskcc) - New York, New York, New York, United States, 10065

Westbury

Clinical Research Alliance, Westbury, New York, United States, 11590

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Daiichi Sankyo,

    Global Clinical Leader, STUDY_DIRECTOR, Daiichi Sankyo

    Study Record Dates

    2028-11-01